Sanofi, AstraZeneca and Sobi simplify Beyfortus agreements ahead of US launch

The modification of an existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of RSV antibody Beyfortus (nirsevimab) and 'enhanced agility' in the US market.